CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL
Clinical trial NCT06926205 · RECRUITING
Trial details
- NCT number
- NCT06926205
- Sponsor
- GELLC (Grupo Español de Leucemia Linfocítica Crónica)
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-15
- Primary completion
- 2028-05-15
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.